Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kymera Therapeutics, Inc.KYMR · Entity 3545 | Director | June 24, 2026 | June 25, 2026 |
| Replimune Group, Inc.REPL · Entity 4707 | Chief Business Officer | September 11, 2023 | September 14, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kymera Therapeutics, Inc.
Report date June 24, 2026 · Filed June 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $99.87 · Expires 2036-06-23 | Direct | 6,068 |
Reported balance
After 2026-06-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-24 · Grant · Acquired 6,068 · Balance 6,068 F1: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 24, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 24, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders.
Replimune Group, Inc.
Report date September 11, 2023 · Filed September 14, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 268,794 |
Reported balance
After 2023-09-11 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-09-11 · Exercise / conversion · Acquired 5,358 · Balance 268,794 |
| Common StockSEC Table I · non-derivative | Direct | 263,436 |
Reported balance
After 2023-09-11 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2023-09-11 · Sale · Disposed 5,358 · Balance 263,436 F1: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on March 15, 2023, that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.05. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| Common StockSEC Table I · non-derivative | Direct | 263,736 |
Reported balance
After 2023-09-12 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2023-09-12 · Exercise / conversion · Acquired 300 · Balance 263,736 |
| Common StockSEC Table I · non-derivative | Direct | 263,436 |
Reported balance
After 2023-09-12 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2023-09-12 · Sale · Disposed 300 · Balance 263,436 F1: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on March 15, 2023, that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F3: Following the sales reported on this Form 4, the reporting person continues to beneficially own 263,436 shares of the Issuer's common stock, including restricted stock units. The reporting person also holds options to acquire an aggregate of 491,569 shares of the Issuer's common stock, 376,774 of which are exercisable as of the date hereof. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.30 · Expires 2027-07-26 | Direct | 86,333 |
Reported balance
After 2023-09-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-09-11 · Exercise / conversion · Disposed 5,358 · Balance 86,333 F4: The reporting person was granted an option to purchase 134,281 shares of the Issuer's common stock on July 26, 2017. All of the shares underlying such stock option have vested and are exercisable as of the date hereof. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.30 · Expires 2027-07-26 | Direct | 86,033 |
Reported balance
After 2023-09-12 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-09-12 · Exercise / conversion · Disposed 300 · Balance 86,033 F4: The reporting person was granted an option to purchase 134,281 shares of the Issuer's common stock on July 26, 2017. All of the shares underlying such stock option have vested and are exercisable as of the date hereof. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on March 15, 2023, that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.
F2: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.05. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3: Following the sales reported on this Form 4, the reporting person continues to beneficially own 263,436 shares of the Issuer's common stock, including restricted stock units. The reporting person also holds options to acquire an aggregate of 491,569 shares of the Issuer's common stock, 376,774 of which are exercisable as of the date hereof.
F4: The reporting person was granted an option to purchase 134,281 shares of the Issuer's common stock on July 26, 2017. All of the shares underlying such stock option have vested and are exercisable as of the date hereof.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 22, 2023 Filed Aug 25, 2023 00:30 UTC | Replimune Group, Inc. REPL · Entity 4707 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 13,600 | $0.00 Strike: $3.30 | $0.00 |
DisclosureSEC source: 0001104659-23-094997 · tm2324763-1_4seq1.xml · derivative · entry 4 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 91,691 Underlying: Common Stock · 13,600 shares Expires 2027-07-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The reporting person was granted an option to purchase 134,281 shares of the Issuer's common stock on July 26, 2017. All of the shares underlying such stock option have vested and are exercisable as of the date hereof. Read SEC document |
| August 22, 2023 Filed Aug 25, 2023 00:30 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 18,600 | $20.01 | $372,186.00 |
DisclosureSEC source: 0001104659-23-094997 · tm2324763-1_4seq1.xml · nonDerivative · entry 3 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 263,436 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on March 15, 2023, that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.04. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · balance_after: Following the sales reported on this Form 4, the reporting person continues to beneficially own 263,436 shares of the Issuer's common stock, including restricted stock units. The reporting person also holds options to acquire an aggregate of 497,227 shares of the Issuer's common stock, 378,873 of which are exercisable as of the date hereof. Read SEC document |
| August 22, 2023 Filed Aug 25, 2023 00:30 UTC | Replimune Group, Inc. REPL · Entity 4707 | Exercise / conversionCommon Stock | 5,000 | $15.50 | $77,500.00 |
DisclosureSEC source: 0001104659-23-094997 · tm2324763-1_4seq1.xml · nonDerivative · entry 2 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 282,036 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 22, 2023 Filed Aug 25, 2023 00:30 UTC | Replimune Group, Inc. REPL · Entity 4707 | Exercise / conversionCommon Stock | 13,600 | $3.30 | $44,880.00 |
DisclosureSEC source: 0001104659-23-094997 · tm2324763-1_4seq1.xml · nonDerivative · entry 1 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 277,036 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 11, 2023 Filed Aug 16, 2023 00:30 UTC | Replimune Group, Inc. REPL · Entity 4707 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,400 | $0.00 Strike: $3.30 | $0.00 |
DisclosureSEC source: 0001104659-23-092111 · tm2323841-1_4seq1.xml · derivative · entry 3 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,291 Underlying: Common Stock · 1,400 shares Expires 2027-07-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The reporting person was granted an option to purchase 134,281 shares of the Issuer's common stock on July 26, 2017. All of the shares underlying such stock option have vested and are exercisable as of the date hereof. Read SEC document |
| August 11, 2023 Filed Aug 16, 2023 00:30 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 1,400 | $20.00 | $28,000.00 |
DisclosureSEC source: 0001104659-23-092111 · tm2323841-1_4seq1.xml · nonDerivative · entry 2 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 263,436 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on March 15, 2023, that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Following the sales reported on this Form 4, the reporting person continues to beneficially own 263,436 shares of the Issuer's common stock, including restricted stock units. The reporting person also holds options to acquire an aggregate of 515,827 shares of the Issuer's common stock, 397,473 of which are exercisable as of the date hereof. Read SEC document |
| August 11, 2023 Filed Aug 16, 2023 00:30 UTC | Replimune Group, Inc. REPL · Entity 4707 | Exercise / conversionCommon Stock | 1,400 | $3.30 | $4,620.00 |
DisclosureSEC source: 0001104659-23-092111 · tm2323841-1_4seq1.xml · nonDerivative · entry 1 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 264,836 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 10, 2023 Filed Jul 12, 2023 01:00 UTC | Replimune Group, Inc. REPL · Entity 4707 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $15.50 | $0.00 |
DisclosureSEC source: 0001104659-23-080113 · tm2321083-1_4seq1.xml · derivative · entry 6 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,750 Underlying: Common Stock · 5,000 shares Expires 2029-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The reporting person was granted an option to purchase 75,750 shares of the Issuer's common stock on April 1, 2019. All of the shares underlying such stock option have vested and are exercisable as of the date hereof. Read SEC document |
| July 10, 2023 Filed Jul 12, 2023 01:00 UTC | Replimune Group, Inc. REPL · Entity 4707 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $3.30 | $0.00 |
DisclosureSEC source: 0001104659-23-080113 · tm2321083-1_4seq1.xml · derivative · entry 5 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,691 Underlying: Common Stock · 15,000 shares Expires 2027-07-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The reporting person was granted an option to purchase 134,281 shares of the Issuer's common stock on July 26, 2017. All of the shares underlying such stock option have vested and are exercisable as of the date hereof. Read SEC document |
| July 10, 2023 Filed Jul 12, 2023 01:00 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 2,077 | $21.12 | $43,866.24 |
DisclosureSEC source: 0001104659-23-080113 · tm2321083-1_4seq1.xml · nonDerivative · entry 4 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 263,436 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on March 15, 2023, that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.09 to $21.17. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F4 · balance_after: Following the sales reported on this Form 4, the reporting person continues to beneficially own 263,436 shares of the Issuer's common stock. The reporting person also holds options to acquire an aggregate of 517,227 shares of the Issuer's common stock, 395,314 of which are exercisable as of the date hereof. Read SEC document |
| July 10, 2023 Filed Jul 12, 2023 01:00 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 17,923 | $21.63 | $387,674.49 |
DisclosureSEC source: 0001104659-23-080113 · tm2321083-1_4seq1.xml · nonDerivative · entry 3 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 265,513 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on March 15, 2023, that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.18 to $22.17. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| July 10, 2023 Filed Jul 12, 2023 01:00 UTC | Replimune Group, Inc. REPL · Entity 4707 | Exercise / conversionCommon Stock | 5,000 | $15.50 | $77,500.00 |
DisclosureSEC source: 0001104659-23-080113 · tm2321083-1_4seq1.xml · nonDerivative · entry 2 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 283,436 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 10, 2023 Filed Jul 12, 2023 01:00 UTC | Replimune Group, Inc. REPL · Entity 4707 | Exercise / conversionCommon Stock | 15,000 | $3.30 | $49,500.00 |
DisclosureSEC source: 0001104659-23-080113 · tm2321083-1_4seq1.xml · nonDerivative · entry 1 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 278,436 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 20:15 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | GrantStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $27.67 | $0.00 |
DisclosureSEC source: 0000899243-23-015961 · doc4.xml · derivative · entry 1 Esposito Pamela · CIK 0001744425 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2033-06-14 F1 · derivative.exercise_date: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 15, 2024 and (ii) the date of the next annual meeting of the Issuer's stockholders. Read SEC document |
| May 16, 2023 Filed May 19, 2023 00:31 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 5,966 | $18.05 | $107,686.30 |
DisclosureSEC source: 0001104659-23-062372 · tm2316199-3_4seq1.xml · nonDerivative · entry 1 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 263,436 F1 · shares: Represents shares of the Issuer's common stock sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units ("RSU"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreement under which the RSU was granted and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.05 to $18.32. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 01, 2023 Filed Apr 5, 2023 00:02 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantEmployee Stock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $17.66 | $0.00 |
DisclosureSEC source: 0001104659-23-041727 · tm2311410-8_4seq1.xml · derivative · entry 2 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2033-04-01 F2 · derivative.exercise_date: 25% of the shares underlying this stock option vest on April 1, 2024, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter. Read SEC document |
| April 01, 2023 Filed Apr 5, 2023 00:02 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-041727 · tm2311410-8_4seq1.xml · nonDerivative · entry 1 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 269,402 F1 · shares: Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2024 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2027, subject to the Reporting Person's continuous service to the Issuer. Read SEC document |
| December 09, 2022 Filed Dec 14, 2022 01:01 UTC | Replimune Group, Inc. REPL · Entity 4707 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $1.01 | $0.00 |
DisclosureSEC source: 0001104659-22-126741 · tm2232604-1_4seq1.xml · derivative · entry 3 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,203 Underlying: Common Stock · 15,000 shares Expires 2025-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The reporting person was granted an option to purchase 149,203 shares of the Issuer's common stock on November 1, 2015. All of the shares underlying such stock option have vested and are exercisable as of the date hereof. Read SEC document |
| December 09, 2022 Filed Dec 14, 2022 01:01 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 15,000 | $25.03 | $375,450.00 |
DisclosureSEC source: 0001104659-22-126741 · tm2232604-1_4seq1.xml · nonDerivative · entry 2 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,402 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on December 13, 2021, that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $25 to $25.14. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · balance_after: Following the sales reported on this Form 4, the reporting person continues to beneficially own 229,402 shares of the Issuer's common stock. The reporting person also holds options to acquire an aggregate of 477,227 shares of the Issuer's common stock, 378,400 of which are exercisable as of the date hereof. Read SEC document |
| December 09, 2022 Filed Dec 14, 2022 01:01 UTC | Replimune Group, Inc. REPL · Entity 4707 | Exercise / conversionCommon Stock | 15,000 | $1.01 | $15,150.00 |
DisclosureSEC source: 0001104659-22-126741 · tm2232604-1_4seq1.xml · nonDerivative · entry 1 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,402 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 15, 2022 Filed Jun 16, 2022 20:06 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | GrantStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $14.18 | $0.00 |
DisclosureSEC source: 0000899243-22-022795 · doc4.xml · derivative · entry 1 Esposito Pamela · CIK 0001744425 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2032-06-14 F1 · derivative.exercise_date: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 15, 2023 and (ii) the date of the next annual meeting of the Issuer's stockholders. Read SEC document |
| May 16, 2022 Filed May 18, 2022 23:03 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 3,507 | $14.59 | $51,167.13 |
DisclosureSEC source: 0001104659-22-062610 · tm2215879-7_4seq1.xml · nonDerivative · entry 1 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,402 F1 · shares: Represents shares of the Issuer's common stock sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units ("RSU"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreement under which the RSU was granted and does not represent a discretionary sale by the Reporting Person. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:15 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantEmployee Stock Option (right to buy) · Derivative | 34,125 | $0.00 Strike: $18.26 | $0.00 |
DisclosureSEC source: 0001104659-22-042762 · tm2211665-6_4seq1.xml · derivative · entry 2 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,125 Underlying: Common Stock · 34,125 shares Expires 2032-04-01 F2 · derivative.exercise_date: 25% of the shares underlying this stock option vest on April 1, 2023, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:15 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantCommon Stock | 22,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-042762 · tm2211665-6_4seq1.xml · nonDerivative · entry 1 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,909 F1 · shares: Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2023 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2026, subject to the Reporting Person's continuous service to the Issuer. Read SEC document |
| August 05, 2021 Filed Aug 7, 2021 01:01 UTC | Replimune Group, Inc. REPL · Entity 4707 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 25,800 | $0.00 Strike: $15.50 | $0.00 |
DisclosureSEC source: 0001104659-21-101719 · tm2124335-1_4seq1.xml · derivative · entry 6 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,750 Underlying: Common Stock · 25,800 shares Expires 2029-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 25% of the shares underlying this stock option vested on April 1, 2020, and the remainder of the shares underlying this stock option vested or will vest, as applicable, in 36 approximately equal monthly installments thereafter. Read SEC document |
| August 05, 2021 Filed Aug 7, 2021 01:01 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 25,800 | $35.09 | $905,322.00 |
DisclosureSEC source: 0001104659-21-101719 · tm2124335-1_4seq1.xml · nonDerivative · entry 4 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,159 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on December 14, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $35 to $35.38. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F4 · balance_after: Following the sales reported on this Form 4, the reporting person continues to beneficially own 210,159 shares of the Issuer's common stock. The reporting person also holds options to acquire an aggregate of 458,102 shares of the Issuer's common stock, 300,811 of which are exercisable as of the date hereof. Read SEC document |
| August 05, 2021 Filed Aug 7, 2021 01:01 UTC | Replimune Group, Inc. REPL · Entity 4707 | Exercise / conversionCommon Stock | 25,800 | $15.50 | $399,900.00 |
DisclosureSEC source: 0001104659-21-101719 · tm2124335-1_4seq1.xml · nonDerivative · entry 3 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,959 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 04, 2021 Filed Aug 7, 2021 01:01 UTC | Replimune Group, Inc. REPL · Entity 4707 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,200 | $0.00 Strike: $15.50 | $0.00 |
DisclosureSEC source: 0001104659-21-101719 · tm2124335-1_4seq1.xml · derivative · entry 5 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,550 Underlying: Common Stock · 4,200 shares Expires 2029-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 25% of the shares underlying this stock option vested on April 1, 2020, and the remainder of the shares underlying this stock option vested or will vest, as applicable, in 36 approximately equal monthly installments thereafter. Read SEC document |
| August 04, 2021 Filed Aug 7, 2021 01:01 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 4,200 | $35.00 | $147,000.00 |
DisclosureSEC source: 0001104659-21-101719 · tm2124335-1_4seq1.xml · nonDerivative · entry 2 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,159 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on December 14, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $35 to $35.05. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 04, 2021 Filed Aug 7, 2021 01:01 UTC | Replimune Group, Inc. REPL · Entity 4707 | Exercise / conversionCommon Stock | 4,200 | $15.50 | $65,100.00 |
DisclosureSEC source: 0001104659-21-101719 · tm2124335-1_4seq1.xml · nonDerivative · entry 1 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,359 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 21, 2021 Filed Jul 23, 2021 01:01 UTC | Replimune Group, Inc. REPL · Entity 4707 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 12,538 | $0.00 Strike: $1.01 | $0.00 |
DisclosureSEC source: 0001104659-21-095084 · tm2123078-1_4seq1.xml · derivative · entry 6 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,203 Underlying: Common Stock · 12,538 shares Expires 2025-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The reporting person was granted an option to purchase 149,203 shares of the Issuer's common stock on November 1, 2015. All of the shares underlying such stock option have vested and are exercisable as of the date hereof. Read SEC document |
| July 21, 2021 Filed Jul 23, 2021 01:01 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 12,538 | $33.17 | $415,885.46 |
DisclosureSEC source: 0001104659-21-095084 · tm2123078-1_4seq1.xml · nonDerivative · entry 4 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,159 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on December 14, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Following the sales reported on this Form 4, the reporting person continues to beneficially own 210,159 shares of the Issuer's common stock. The reporting person also holds options to acquire an aggregate of 488,102 shares of the Issuer's common stock, 324,649 of which are exercisable as of the date hereof. Due to scrivener's error, footnote 2 of the Form 4 filed on behalf of the reporting person on July 19, 2021 inadvertently overstated the number of options held by the Reporting Person following the transaction reported therein. The amounts stated in this footnote 2 set forth the correct number of options held by the Reporting Person following the transaction reported herein. Read SEC document |
| July 21, 2021 Filed Jul 23, 2021 01:01 UTC | Replimune Group, Inc. REPL · Entity 4707 | Exercise / conversionCommon Stock | 12,538 | $1.01 | $12,663.38 |
DisclosureSEC source: 0001104659-21-095084 · tm2123078-1_4seq1.xml · nonDerivative · entry 3 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,697 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 20, 2021 Filed Jul 23, 2021 01:01 UTC | Replimune Group, Inc. REPL · Entity 4707 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,862 | $0.00 Strike: $1.01 | $0.00 |
DisclosureSEC source: 0001104659-21-095084 · tm2123078-1_4seq1.xml · derivative · entry 5 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,741 Underlying: Common Stock · 4,862 shares Expires 2025-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The reporting person was granted an option to purchase 149,203 shares of the Issuer's common stock on November 1, 2015. All of the shares underlying such stock option have vested and are exercisable as of the date hereof. Read SEC document |
| July 20, 2021 Filed Jul 23, 2021 01:01 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 4,862 | $33.05 | $160,689.10 |
DisclosureSEC source: 0001104659-21-095084 · tm2123078-1_4seq1.xml · nonDerivative · entry 2 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,159 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on December 14, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. Read SEC document |
| July 20, 2021 Filed Jul 23, 2021 01:01 UTC | Replimune Group, Inc. REPL · Entity 4707 | Exercise / conversionCommon Stock | 4,862 | $1.01 | $4,910.62 |
DisclosureSEC source: 0001104659-21-095084 · tm2123078-1_4seq1.xml · nonDerivative · entry 1 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,021 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 15, 2021 Filed Jul 20, 2021 01:02 UTC | Replimune Group, Inc. REPL · Entity 4707 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,600 | $0.00 Strike: $1.01 | $0.00 |
DisclosureSEC source: 0001104659-21-093671 · tm2122438-2_4seq1.xml · derivative · entry 3 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,603 Underlying: Common Stock · 4,600 shares Expires 2025-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The reporting person was granted an option to purchase 149,203 shares of the Issuer's common stock on November 1, 2015. All of the shares underlying such stock option have vested and are exercisable as of the date hereof. Read SEC document |
| July 15, 2021 Filed Jul 20, 2021 01:02 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 4,600 | $33.37 | $153,502.00 |
DisclosureSEC source: 0001104659-21-093671 · tm2122438-2_4seq1.xml · nonDerivative · entry 2 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,159 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on December 14, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Following the sales reported on this Form 4, the reporting person continues to beneficially own 210,159 shares of the Issuer's common stock. The reporting person also holds options to acquire an aggregate of 544,267 shares of the Issuer's common stock, 345,191 of which are exercisable as of the date hereof. Read SEC document |
| July 15, 2021 Filed Jul 20, 2021 01:02 UTC | Replimune Group, Inc. REPL · Entity 4707 | Exercise / conversionCommon Stock | 4,600 | $1.01 | $4,646.00 |
DisclosureSEC source: 0001104659-21-093671 · tm2122438-2_4seq1.xml · nonDerivative · entry 1 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,759 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 16, 2021 Filed Jun 17, 2021 20:50 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | GrantStock Option (Right to Buy) · Derivative | 20,063 | $0.00 Strike: $49.10 | $0.00 |
DisclosureSEC source: 0000899243-21-024447 · doc4.xml · derivative · entry 1 Esposito Pamela · CIK 0001744425 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,063 Underlying: Common Stock · 20,063 shares Expires 2031-06-15 F1 · derivative.exercise_date: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 16, 2022 and (ii) the date of the next annual meeting of the Issuer's stockholders. Read SEC document |
| April 01, 2021 Filed Apr 6, 2021 00:20 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantEmployee Stock Option (right to buy) · Derivative | 51,250 | $0.00 Strike: $31.58 | $0.00 |
DisclosureSEC source: 0001104659-21-046734 · tm2112099-14_4seq1.xml · derivative · entry 2 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,250 Underlying: Common Stock · 51,250 shares Expires 2031-04-01 F2 · derivative.exercise_date: 25% of the shares underlying this stock option vest on April 1, 2022, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter. Read SEC document |
| April 01, 2021 Filed Apr 6, 2021 00:20 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantCommon Stock | 34,165 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-046734 · tm2112099-14_4seq1.xml · nonDerivative · entry 1 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,159 F1 · shares: Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2022 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2025, subject to the Reporting Person's continuous service to the Issuer. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 02:50 UTC | Replimune Group, Inc. REPL · Entity 4707 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,727 | $0.00 Strike: $1.01 | $0.00 |
DisclosureSEC source: 0001104659-21-005570 · tm213368-5_4seq1.xml · derivative · entry 10 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,203 Underlying: Common Stock · 5,727 shares Expires 2025-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The reporting person was granted an option to purchase 149,203 shares of the Issuer's common stock on November 1, 2015. All of the shares underlying such stock option have vested and are exercisable as of the date hereof. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 02:50 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 5,127 | $42.38 | $217,282.26 |
DisclosureSEC source: 0001104659-21-005570 · tm213368-5_4seq1.xml · nonDerivative · entry 7 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,994 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on December 14, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.76. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F4 · balance_after: Following the sales reported on this Form 4, the reporting person continues to beneficially own 175,994 shares of the Issuer's common stock. The reporting person also holds options to acquire an aggregate of 497,852 shares of the Issuer's common stock, 458,852 of which are exercisable as of the date hereof. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 02:50 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 600 | $43.24 | $25,944.00 |
DisclosureSEC source: 0001104659-21-005570 · tm213368-5_4seq1.xml · nonDerivative · entry 6 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,121 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on December 14, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.88 to $43.86. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 02:50 UTC | Replimune Group, Inc. REPL · Entity 4707 | Exercise / conversionCommon Stock | 5,727 | $1.01 | $5,784.27 |
DisclosureSEC source: 0001104659-21-005570 · tm213368-5_4seq1.xml · nonDerivative · entry 5 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,721 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 19, 2021 Filed Jul 20, 2021 01:02 UTC Amendment | Replimune Group, Inc. REPL · Entity 4707 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,727 | $0.00 Strike: $1.01 | $0.00 |
DisclosureSEC source: 0001104659-21-093670 · tm2122438-3_4aseq1.xml · derivative · entry 10 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,203 Underlying: Common Stock · 5,727 shares Expires 2025-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The reporting person was granted an option to purchase 149,203 shares of the Issuer's common stock on November 1, 2015. All of the shares underlying such stock option have vested and are exercisable as of the date hereof. Read SEC document |
| January 19, 2021 Filed Jul 20, 2021 01:02 UTC Amendment | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 5,127 | $42.38 | $217,282.26 |
DisclosureSEC source: 0001104659-21-093670 · tm2122438-3_4aseq1.xml · nonDerivative · entry 7 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,994 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on December 14, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.76. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F4 · balance_after: Following the sales reported on this Form 4, the reporting person continues to beneficially own 175,994 shares of the Issuer's common stock. The reporting person also holds options to acquire an aggregate of 458,852 shares of the Issuer's common stock, 284,936 of which are exercisable as of the date hereof. The original Form 4 filed on January 19, 2021 is being amended by this Form 4 solely to correct an administrative error, which misreported the total number of options held by the reporting person and the amount exercisable as of January 19, 2021. Read SEC document |
| January 19, 2021 Filed Jul 20, 2021 01:02 UTC Amendment | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 600 | $43.24 | $25,944.00 |
DisclosureSEC source: 0001104659-21-093670 · tm2122438-3_4aseq1.xml · nonDerivative · entry 6 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,121 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on December 14, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.88 to $43.86. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 19, 2021 Filed Jul 20, 2021 01:02 UTC Amendment | Replimune Group, Inc. REPL · Entity 4707 | Exercise / conversionCommon Stock | 5,727 | $1.01 | $5,784.27 |
DisclosureSEC source: 0001104659-21-093670 · tm2122438-3_4aseq1.xml · nonDerivative · entry 5 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,721 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.